Drug intelligence / Profile preview

motesanib + panitumumab

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Motesanib + panitumumab is a combination therapy consisting of motesanib, an orally administered small-molecule antagonist of vascular endothelial growth factor receptors (VEGFR1, 2, and 3), platelet-derived growth factor receptor (PDGFR), and Kit, along with panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody. This combination has been studied in clinical trials for advanced solid tumors, particularly in the context of cancer treatment regimens that may also include chemotherapy agents.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFR (PDGFR family)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)EGFR T790M (Epidermal growth factor receptor T790M mutant)KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on motesanib + panitumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on motesanib + panitumumab.

Explore the full profile